多发性骨髓瘤的特克利斯塔马布:临床见解和实践考虑为一流的双特异性抗体
1Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Cancer management and research
|July 27, 2023
概括
双特异性抗体Teclistamab为复发性或耐火性多发性髓瘤提供了新的希望. 虽然有效,但需要仔细管理副作用,如细胞因子释放综合征 (CRS).
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- 多发性骨髓瘤是一种血液性恶性瘤,对于复发或耐药病例的治疗选择有限.
- 针对B细胞成熟抗原 (BCMA) 和CD3的双特异性抗体代表了一种新的治疗方法.
- 德克利斯塔马布是首个经批准用于复发性或耐火性多发性髓瘤的BCMAxCD3双特异性抗体.
研究的目的:
- 审查支持teclistamab批准的临床前和临床数据.
- 讨论患者选择,不良事件的管理,以及多发性骨髓瘤双特异抗体治疗的未来方向.
主要方法:
- 对研究德克利斯塔马布的作用机制和疗效的临床前研究的综述.
- 对临床试验数据的分析,评估teclistamab在复发性或耐火性多发性髓瘤患者的安全性和有效性.
- 综合了有关管理策略的信息,以解决与德克利斯塔马布相关的毒性问题.
主要成果:
- 在重复性或耐火性多发性骨髓瘤的重度预治疗患者中,特克利斯塔马布显示出显著的疗效.
- 值得注意的不良影响包括细胞因子释放综合征 (CRS),感染和神经毒性.
- 与BCMA指导的CAR T细胞疗法相比,特克利斯塔马布提供了更好的可访问性.
结论:
- 德基利斯塔马布有望成为复发性或耐火性多发性髓瘤的关键治疗方法.
- 积极管理不良事件,特别是CRS,对于安全有效的使用至关重要.
- 对双特异性抗体治疗的进一步研究可能会扩大多发性髓瘤的治疗范式.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
01:27Tumor Immunotherapy
558
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
558
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K